Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Form 8.3 - Amendment

23 Jan 2026 16:59

RNS Number : 2321Q
Serum Life Sciences
23 January 2026
 

The Form 8.3 announcement released today at 16.36 under RNS No 2275Q, should have been issued under the Company name of Serum Life Sciences Ltd and not under the Company name of Sareum Holdings PLC.

 

The announcement text is unchanged and is reproduced in full below.

 

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Serum Life Sciences Ltd

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and

beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Oxford Biomedica plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

23 January 2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

3,771,098

3.12

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

3,771,098

3.12

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a

long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description

e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which

option relates

Exercise price per unit

Type

e.g.

American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii)  the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

Date of disclosure:

23 January 2026

Contact name:

Andrew Coll

Telephone number*:

0203 746 6137

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETEAKFDASLKEFA
Date   Source Headline
30th Jun 201710:38 amRNSRefinancing of Debt Facility
23rd Jun 201710:12 amRNSDirector Dealings / Market Share Purchase
14th Jun 20173:00 pmRNSFindings from Phase II JULIET Study
7th Jun 20177:00 amRNSOXB notes FDA Advisory Committee to review CTL019
2nd Jun 20177:00 amRNSOXB to Present at Jefferies Healthcare Conference
1st Jun 201712:22 pmRNSTotal Voting Rights
24th May 20171:55 pmRNSDirector/PDMR Shareholding
23rd May 20172:03 pmRNSResult of AGM
4th May 20178:46 amRNSTotal Voting Rights
28th Apr 20177:00 amRNSAnnual Report and Accounts & AGM Notification
24th Apr 201710:17 amRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20179:11 amRNSTotal Voting Rights
31st Mar 20177:15 amRNSHardman: Delivering commercial gene-therapy vector
30th Mar 20177:02 amRNSBLA filing for CTL019
27th Mar 201710:44 amRNSPublication in the Journal Nature Communications
23rd Mar 20171:47 pmRNSDirector Dealings
22nd Mar 20177:00 amRNSHolding(s) in Company
16th Mar 20177:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10th Mar 20177:00 amRNSNotice of Preliminary Results
1st Mar 201710:24 amRNSTotal Voting Rights
28th Feb 20177:00 amRNSAppointment of New Chief Financial Officer
24th Feb 20179:36 amRNSDirector Dealings
24th Feb 20177:00 amRNSResults of TroVax® in Advanced Colorectal Cancer
1st Feb 201710:09 amRNSTotal Voting Rights
25th Jan 20179:02 amRNSDirector/PDMR Shareholding
24th Jan 20174:34 pmRNSDirector Dealings / Market Share Purchase
24th Jan 20179:31 amRNSDirector/PDMR Shareholding
23rd Jan 20179:57 amRNSDirector/PDMR Shareholding
3rd Jan 20179:30 amRNSBlock Listing Return
3rd Jan 20179:28 amRNSTotal Voting Rights
20th Dec 20168:57 amRNSDirector/PDMR Shareholding
12th Dec 201610:52 amRNSBlock listing application
6th Dec 20169:15 amRNSDirector/PDMR Shareholding
5th Dec 201610:25 amRNSFindings Reported by Novartis on CTL-019 at ASH
5th Dec 20169:43 amRNSDirector/PDMR Shareholding
1st Dec 20169:27 amRNSTotal Voting Rights
29th Nov 20167:00 amRNSStrategic Alliance with Orchard Therapeutics
28th Nov 201610:06 amRNSDirector/PDMR Shareholding
8th Nov 20166:28 pmRNSGrant of options (Replacement)
8th Nov 20166:13 pmRNSGrant of options
1st Nov 201610:21 amRNSTotal Voting Rights
25th Oct 20164:40 pmRNSDirector/PDMR Shareholding
10th Oct 20167:21 amRNSPublication of RetinoStat® (OXB-201) Phase I study
6th Oct 20169:24 amRNSHolding(s) in Company
5th Oct 201610:17 amRNSHolding(s) in Company
4th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20168:16 amRNSAdmission to Trading and Total Voting Rights
29th Sep 201612:27 pmRNSResult of General Meeting and Directors Dealing
26th Sep 201611:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.